31 research outputs found
La Jornada Laboral en España: evolución y obligatoriedad de registro
En el presente trabajo se pretende llevar a cabo un estudio acerca de la nueva redacción del artículo 34.9 del ET, por medio de la cual se establece la obligatoriedad del registro de la jornada laboral para todos los trabajadores aprobada con el RDL 8/2019. La novedad de la medida, así como el gran cambio de rumbo en la regulación y control de la jornada de los trabajadores en España se pueden considerar motivos de suficiente interés como para llevar a cabo un estudio de tales características, y de esta forma, poder conocer un poco más acerca de la nueva regulación, pudiendo prever todas las futuras consecuencias en beneficio de los trabajadores de ahora en adelante, fruto de un control mucho más exhaustivo en garantía de una mayor calidad laboral.Para el estudio, se parte de los conceptos básicos de jornada laboral y tiempo efectivo de trabajo en España, haciendo hincapié en el derecho de desconexión tecnológica de los trabajadores durante sus permisos, descansos o vacaciones. Posteriormente, una breve recapitulación de su evolución desde comienzos del siglo XIX, hasta la última modificación legislativa comentada anteriormente en 2019 y a través de la cual se impone la obligación al empresario de registrar la jornada de los trabajadores diariamente, incluyendo tanto la parte de horas ordinarias, como extraordinarias.Por último, se plantea la relación o posible confrontación de los sistemas de registro para el control de la jornada, así como de los dispositivos electrónicos sobre los que se procede al estudio relativo al derecho de desconexión tecnológica, desde el punto de vista de la Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y garantía de los derechos digitales.<br /
Identification of a novel quinoxaline-isoselenourea targeting the STAT3 pathway as a potential melanoma therapeutic
The prognosis for patients with metastatic melanoma remains very poor. Constitutive
signal transducer and activator of transcription 3 (STAT3) activation has been correlated to metastasis,
poor patient survival, larger tumor size, and acquired resistance against vemurafenib (PLX-4032),
suggesting its potential as a molecular target. We recently designed a series of isoseleno- and
isothio-urea derivatives of several biologically active heterocyclic scaffolds. The cytotoxic effects
of lead isoseleno- and isothio-urea derivatives (compounds 1 and 3) were studied in a panel of
five melanoma cell lines, including B-RAFV600E-mutant and wild-type (WT) cells. Compound 1
(IC50 range 0.8–3.8 µM) showed lower IC50 values than compound 3 (IC50 range 8.1–38.7 µM) and
the mutant B-RAF specific inhibitor PLX-4032 (IC50 ranging from 0.4 to >50 µM), especially at a
short treatment time (24 h). These effects were long-lasting, since melanoma cells did not recover
their proliferative potential after 14 days of treatment. In addition, we confirmed that compound 1
induced cell death by apoptosis using Live-and-Dead, Annexin V, and Caspase3/7 apoptosis assays.
Furthermore, compound 1 reduced the protein levels of STAT3 and its phosphorylation, as well as
decreased the expression of STAT3-regulated genes involved in metastasis and survival, such as
survivin and c-myc. Compound 1 also upregulated the cell cycle inhibitor p21. Docking studies
further revealed the favorable binding of compound 1 with the SH2 domain of STAT3, suggesting it
acts through STAT3 inhibition. Taken together, our results suggest that compound 1 induces apoptosis
by means of the inhibition of the STAT3 pathway, non-specifically targeting both B-RAF-mutant and
WT melanoma cells, with much higher cytotoxicity than the current therapeutic drug PLX-4032
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Altres ajuts: This work was funded by CIBERNED grant ; Fundació la Marató de TV3 grants 20141210;, 20142610;, and 20161431; , and PI18/00435 ; and SLT006/17/95; la Caixa Foundation grant. Instituto de Salud Carlos III grants PI13/01532To determine the cutoffs that optimized the agreement between 18 F-Florbetapir positron emission tomography (PET) and A β 1-42, A β 1-40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on Neurodegeneration (SPIN cohort) using the Lumipulse G System with available 18 F-Florbetapir imaging. Participants had mild cognitive impairment (n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases (n = 41), or were cognitively normal controls (n = 6). Levels of A β 1-42 were standardized to certified reference material. Amyloid scans were assessed visually and through automated quantification. We determined the cutoffs of CSF biomarkers that optimized their agreement with 18 F-Florbetapir PET and evaluated concordance between markers of the amyloid category. A β 1-42, tTau and pTau (but not A β 1-40) and the ratios with A β 1-42 had good diagnostic agreement with 18 F-Florbetapir PET. As a marker of amyloid pathology, the A β 1-42/A β 1-40 ratio had higher agreement and better correlation with amyloid PET than A β 1-42 alone. CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of A β 1-42 with A β 1-40 increases the agreement between markers of amyloid pathology
Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
The protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disease, the most important parasitic infection in Latin America. The only treatments currently available are nitro-derivative drugs that are characterised by high toxicity and limited efficacy. Therefore, there is an urgent need for more effective, less toxic therapeutic agents. We have previously identified the potential for Mannich base derivatives as novel inhibitors of this parasite. To further explore this family of compounds, we synthesised a panel of 69 new analogues, based on multi-parametric structure-activity relationships, which allowed optimization of both anti-parasitic activity, physicochemical parameters and ADME properties. Additionally, we optimized our in vitro screening approaches against all three developmental forms of the parasite, allowing us to discard the least effective and trypanostatic derivatives at an early stage. We ultimately identified derivative 3c, which demonstrated excellent trypanocidal properties, and a synergistic mode of action against trypomastigotes in combination with the reference drug benznidazole. Both its druggability and low-cost production make this derivative a promising candidate for the preclinical, in vivo assays of the Chagas disease drug-discovery pipeline
Library of Seleno-Compounds as Novel Agents against Leishmania Species
The in vitro leishmanicidal activities of a series of 48 recently synthesized selenium derivatives against Leishmania infantum and Leishmania braziliensis parasites were tested using promastigotes and intracellular amastigote forms. The cytotoxicity of the tested compounds for J774.2 macrophage cells was also measured in order to establish their selectivity. Six of the tested compounds (compounds 8, 10, 11, 15, 45, and 48) showed selectivity indexes higher than those of the reference drug, meglumine antimonate (Glucantime), for both Leishmania species; in the case of L. braziliensis, compound 20 was also remarkably selective. Moreover, data on infection rates and amastigote numbers per macrophage showed that compounds 8, 10, 11, 15, 45, and 48 were the most active against both Leishmania species studied. The observed changes in the excretion product profile of parasites treated with these six compounds were also consistent with substantial cytoplasmic alterations. On the other hand, the most active compounds were potent inhibitors of Fe superoxide dismutase (Fe-SOD) in the two parasite species considered, whereas their impact on human CuZn-SOD was low. The high activity, low toxicity, stability, low cost of the starting materials, and straightforward synthesis make these compounds appropriate molecules for the development of affordable antileishmanicidal agents
Cambios en la etiología, incidencia y pronóstico de la infección respiratoria aguda de vías bajas en pacientes infectados por el virus de la inmunodeficiencia humana
Aim To describe the, incidence, the changes in the etiology and the prognosis of lower respiratory tract infection (LRTI) in HIV infected patients, presenting by the first time to the Emergency Department (ED), during years 2000-2010. Study design Prospective collection of data. Metbods Data were collected on the first visit of HIV-infected patients at our ED due to a LRTI, (defined according to the criteria of the European Respiratory Society), between 1/1/2000 and 31/12/2010. A series of epidemiological and laboratory variables as well as the need for admission to the intensive care unit (ICU). LRTI etiology were also collected. The influence ofthe mentioned variables on 30-day mortality were analyzed. Results One hundred thirty one patients were included. LRTI represented 27% of visits to the ED by HIV-infected patients. Mean age was 39±9 years. 72% of patients were males. 18% required admission to the ICU. The most frequent LRTI was pneumonia by P. jiroveci in 35 cases, bacterial penumonia in 27 and pulmonary tuberculosis in 20. LRTI incidence gradually reduced significantly over time from 6.13 × 1000 patients/year in year 2000 to 0.23 × 1000 patients/year in 2010 (p<0.05). Overall mortality was 14%. Logistic regression analysis showed that admission to ICU (p<0.004) and viral load (p<0.029) were independent variables predicting mortality. Conclusion LRTI is a pathology with a decreasing incidence, probably related to the widespread utilization increased of HAART regimens. lts etiology has also been changing, but with a non negligible mortality, mostly when ICU admission was required.Objetivo
Describir la incidencia, la etiología y el pronóstico de la infección de las vías espiratorias bajas (IVRB) en los pacientes VIH, que acudieron a un Servicio de Urgencias (SU), durante el período del 2000–2010.
Diseño del estudio
Estudio prospectivo de 10 años de evolución.
Métodos
Se recogió únicamente el primer episodio del paciente que acude al SU por IRVB (definida según la European Respiratory Society). Se analizaron una serie de variables epidemiológicas y de laboratorio, así como la necesidad de ingreso en una unidad de cuidados intensivos (UCI). Se estudió la etiología de la IRVB y la incidencia. Finalmente se analizaron la influencia de las variables con la mortalidad a 30 días.
Resultados
Se incluyeron un total de 131 pacientes. La edad media fue de 39 ± 9 años. El 72% de los pacientes eran varones y el 18% de los pacientes requirieron ingreso en la UCI. La IRVB más frecuente fue la neumonía por P. jirovecci, seguida de la neumonía bacteriana en 27 y la tuberculosis pulmonar en 20. La incidencia de IRVB se ha ido reduciendo gradualmente de forma significativa, 6,13 × 1.000 pacientes/año en 2000 a 0,23 × 1.000 pacientes/año en 2010 (p < 0,05). El análisis de regresión logística mostró que la única variable que predijo mortalidad fue el ingreso en UCI (p < 0,05; OR: 73,01).
Conclusión
La IRVB es una enfermedad cuya incidencia y etiología han ido disminuyendo y cambiando respectivamente, probablemente en relación con la utilización generalizada del TAR. Sin embargo, todavía presenta una mortalidad nada despreciable, que es mayor cuando el paciente requiere ingreso en la UCI
The antibiotic resistance-free vaccine based on the non-replicative pPAL vector is fully protective against SARS-CoV-2 in the murine model
1 p.Background. The main objective of this work is the development of a DNA vaccine against the SARS-CoV-2 virus based on the non-replicative antibiotic resistance marker gene-free the plasmid vector pPAL.Methods. We designed pPAL-Sfs and pPAL-structural protein constructs. A PCR cloning procedure was carried out to obtain the pPAL-based recombinant vaccine and laboratory-scale batches of pPAL-based SARS-CoV-2 vaccine constructs were produced. Transfection was performed on the human HEK293 cell line with the pPAL-based recombinant vaccine. Expression was evaluated by Western blot. Evaluation of protection experiments against a lethal dose of 105 pfu of SARS-CoV-2 (Wuhan-Hu-1 and Delta strains) in K18-hACE2 female mice vaccinated intramuscularly with a prime/boost regimen was carried out by assessing both humoral and cellular immune responses. ELISA was used to evaluate humoral immunity, namely total IgG, as well as IgG1 and IgG2c subclasses. The cellular immune response was evaluated by quantifying the rate of IFN-γ producing splenocyte clones used ELISpot. In addition, characterization of the cellular response was carried out by intracellular staining (ICS) to identify of the rate of IFN-γ and TNF-α producing TCD4+ lymphocytes, as well as the proportion of TCD8+ lymphocytes. Determination of viral load in the main target organs was done by RT-PCR (lungs, heart, and brain). Virus replication capacity was also evaluated in target organs tissues. In vitro
assays were performed out to determine the levels of neutralizing antibodies against SARS-CoV-2 virus.Results. The results show 100% protection of vaccinated animals in terms of symptomatology, animal weight, level of neutralizing antibodies against the virus and the rate of IFN-γ and TNF-α producing splenocyte clones. The analysis of IgG subclasses shows a predominance of IgG2c over IgG1, indicating the activation of a specific and cytotoxic Th1 protective cellular immune response and immunological memory. Finally, a reduction of viral load has been observed in vaccinated animals, with a clear reduction of virus replication in the main target organs. Furthermore, there is a synergistic effect increasing protection using the two plasmids p-PALSfs + pPAL-structural protein (under patent).Conclusions. The DNA vaccine pPAL-Sfs + pPAL-structural protein is fully protective in the mouse model in terms of maintenance of body weight, absence of significant clinical signs, viral load clearance in target organs and immune response. The immune response included neutralizing antibodies, predominance of IgG2c over IgG1 ratio, a Th1 response, and a multifunctional cytotoxic cellular response.Peer reviewe
Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2
17 p.-8 fig.SARS-CoV-2 vaccines currently in use have contributed to controlling the COVID-19 pandemic. Notwithstanding, the high mutation rate, fundamentally in the spike glycoprotein (S), is causing the emergence of new variants. Solely utilizing this antigen is a drawback that may reduce the efficacy of these vaccines. Herein we present a DNA vaccine candidate that contains the genes encoding the S and the nucleocapsid (N) proteins implemented into the non-replicative mammalian expression plasmid vector, pPAL. This plasmid lacks antibiotic resistance genes and contains an alternative selectable marker for production. The S gene sequence was modified to avoid furin cleavage (Sfs). Potent humoral and cellular immune responses were observed in C57BL/6J mice vaccinated with pPAL-Sfs + pPAL-N following a prime/boost regimen by the intramuscular route applying in vivo electroporation. The immunogen fully protected K18-hACE2 mice against a lethal dose (105 PFU) of SARS-CoV-2. Viral replication was completely controlled in the lungs, brain, and heart of vaccinated mice. Therefore, pPAL-Sfs + pPAL-N is a promising DNA vaccine candidate for protection from COVID-19.This work was funded by PTI-Salud Global (CSIC), Center for Technological and Industrial Development (CDTI), REACT-ANTICIPA-UCM (Comunidad de Madrid), and European Research Council (Advanced Grant VERDI, ERC2015AdG grant number 694160).Peer reviewe
Role of age and comorbidities in mortality of patients with infective endocarditis
[Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality.
[Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk.
[Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality.
[Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group
Potential of sulfur-selenium isosteric replacement as a strategy for the development of new anti-chagasic drugs
Current treatment for Chagas disease is based on only two drugs: benznidazole and nifurtimox. Compounds containing sulfur (S) in their structure have shown promising results in vitro and in vivo against Trypanosoma cruzi, the parasite causing Chagas disease. Notably, some reports show that the isosteric replacement of S by selenium (Se) could be an interesting strategy for the development of new compounds for the treatment of Chagas disease. To date, the activity against T. cruzi of three Se- containing groups has been compared with their S counterparts: selenosemicarbazones, selenoquinones, and selenocyanates. More studies are needed to confirm the positive results of Se compounds. Therefore, we have investigated S compounds described in the literature tested against T. cruzi. We focused on those tested in vivo that allowed isosteric replacement to propose their Se counterparts as promising compounds for the future development of new drugs against Chagas disease